Glimzab M 1mg/500mg Tablet PR is a combination oral hypoglycemic agent containing Glimepiride 1mg and Metformin 500mg, indicated for the management of type 2 diabetes mellitus. Glimepiride, a sulfonylurea class drug, stimulates pancreatic beta cells to increase insulin secretion, thereby improving glycemic control. Metformin, a biguanide, primarily acts by decreasing hepatic glucose production and enhancing peripheral glucose uptake and utilization, contributing to improved insulin sensitivity. The combination of these agents provides complementary mechanisms to achieve better glycemic regulation in patients inadequately controlled on diet and exercise alone or on monotherapy. Glimzab M is typically prescribed as part of a comprehensive diabetes management plan, including diet modification and physical activity. It is contraindicated in patients with type 1 diabetes, diabetic ketoacidosis, severe renal or hepatic impairment, and conditions predisposing to hypoxia. Common adverse effects may include gastrointestinal disturbances such as nausea, vomiting, and diarrhea, as well as hypoglycemia due to Glimepiride. Regular monitoring of blood glucose levels, renal function, and periodic assessment of HbA1c is recommended to optimize therapy and minimize risks. Patient education on adherence and recognition of hypoglycemia symptoms is essential for safe and effective use.